rs12979860 — IFNL4

IFNL4 — The Antiviral Immunity Switch

When your body encounters a viral infection in the liver or airways, it deploys type III interferons¹¹ type III interferons
a family of antiviral signalling proteins that activate the JAK-STAT pathway and interferon-stimulated genes in epithelial and hepatocyte cells as a first line of defence. The IFNL4 gene on chromosome 19q13.2 encodes interferon lambda-4²² interferon lambda-4
one of four interferon lambda proteins (IFNL1–4) that restrict viral replication at mucosal and hepatic barriers, but only in people who carry the T allele at rs12979860. Carriers of the CC genotype produce no functional IFN-λ4 protein at all — their IFNL4 gene is silenced — and paradoxically, this silencing is protective against hepatitis C.

rs12979860 was originally attributed to the nearby IL28B (IFNL3) gene in the landmark 2009 GWAS studies. The discovery in 2013 that the variant actually lies in intron 1 of a newly identified gene, IFNL4, resolved the biological mystery of how an intronic change could exert such profound effects on viral clearance.

The Mechanism

The rs12979860 C>T variant is in strong linkage disequilibrium³³ linkage disequilibrium
non-random co-inheritance of nearby variants with a dinucleotide frameshift variant (ss469415590 TT/ΔG) that either creates or destroys IFNL4 as a functional gene. The T allele at rs12979860 tags the ΔG allele, which generates a functional IFNL4-encoded protein with genuine antiviral activity. The C allele tags the TT allele, which is a loss-of-function that silences IFNL4 entirely.

The apparent paradox — a functional interferon protein impairing viral clearance — is explained by recent mechanistic work. IFN-λ4 is largely retained in the endoplasmic reticulum⁴⁴ IFN-λ4 is largely retained in the endoplasmic reticulum
it fails to be secreted efficiently rather than being released to activate neighbouring cells. Instead, ER-retained IFN-λ4 induces ER stress, and ER-stressed hepatocytes are substantially weaker activators of HCV-specific CD8+ T cells, crippling the adaptive immune response needed to eradicate the virus. Additionally, chronic IFN-λ4 signalling causes pre-activation of interferon-stimulated genes (ISGs) that desensitises hepatocytes to exogenous interferon treatment — explaining both natural and treatment-related impairment.

The Evidence

The 2009 GWAS studies identified rs12979860 as the strongest host genetic predictor of HCV treatment response⁵⁵ strongest host genetic predictor of HCV treatment response
measured as sustained virologic response, SVR, meaning undetectable virus 12–24 weeks after completing therapy, with an odds ratio of approximately 5.8 for SVR in European patients carrying CC versus non-CC (TT/CT) genotypes. In a Japanese cohort, SVR rates were 76.9% in CC, 56.4% in CT, and 12.5% in TT patients⁶⁶ 76.9% in CC, 56.4% in CT, and 12.5% in TT patients receiving peginterferon/ribavirin.

For spontaneous viral clearance (never needing treatment at all), a meta-analysis of 17 studies⁷⁷ meta-analysis of 17 studies found rs12979860 CC confers OR 2.98 (95% CI 2.53–3.50) for HCV elimination without treatment versus CT or TT genotypes. The effect is stronger in Caucasian and African populations than in Asians, where the favourable C allele is near-universal (East Asian T allele frequency ~0.04).

Beyond HCV, the T allele has been associated with impaired viral defences more broadly. A Spanish study found the T allele was overrepresented in COVID-19 patients⁸⁸ the T allele was overrepresented in COVID-19 patients relative to the general population (36.2% vs 26.4%; OR 0.63 for the protective C allele, p=6.4×10⁻⁴). The variant's role in hepatitis B clearance is debated — some studies show the CC genotype predicts HBsAg seroclearance in interferon-treated HBeAg-negative patients, while others find no effect on untreated HBV natural history.

With modern direct-acting antiviral (DAA) regimens for HCV, the IFNL4 variant retains clinical relevance. In the pivotal NEUTRINO trial of sofosbuvir-based therapy, SVR12 was 99% in CC versus 87% in non-CC patients⁹⁹ SVR12 was 99% in CC versus 87% in non-CC patients, and the IFNL4-ΔG genotype is specifically associated with slower early viral decay kinetics even with DAA treatment, influencing whether shorter (8-week) treatment courses can be used safely.

The variant is also an aetiology-independent predictor of liver fibrosis: in a cohort of 4,172 patients with diverse liver diseases¹⁰¹⁰ 4,172 patients with diverse liver diseases — including NAFLD — those with non-CC genotypes (carrying the T/ΔG allele) showed greater hepatic inflammation and fibrosis, confirming IFNL4 signalling promotes liver inflammation beyond viral contexts.

Practical Actions

People with CT or TT genotypes who have ever been exposed to hepatitis C or are at risk should discuss screening and, if infected, the implications for treatment duration with their doctor. While DAA therapy achieves high cure rates even with unfavourable genotypes, the IFNL4 genotype affects how quickly the virus clears and whether shorter treatment protocols are suitable.

For TT carriers who were treated with older peginterferon-based regimens and failed — this failure was largely biologically predetermined, and modern DAA regimens offer a much better chance of cure.

The broader implication for viral immunity (COVID-19, other respiratory viruses) is emerging but suggests that CT and TT carriers have a subtly impaired first-line antiviral response at hepatic and mucosal surfaces. Prioritising vaccination against preventable infections is a rational response.

Interactions

rs12979860 is in strong linkage disequilibrium with rs8099917¹¹¹¹ rs8099917
another IFNL locus variant frequently used for HCV pharmacogenomics testing, r²=0.43–0.65 depending on population and with rs12980275¹²¹² rs12980275
third IFNL3 region variant, r²=0.68–1.0 with rs12979860. Commercial HCV pharmacogenomics panels often report all three; rs12979860 is generally considered the most predictive. The variants should not be summed as independent effects — they tag the same underlying IFNL4 functional state.